$3M Gene Therapy—With a Catch - Scorecard - MDSpire

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Clinical Scorecard: $3M Gene Therapy—With a Catch

At a Glance

CategoryDetail
ConditionSickle Cell Disease
Key MechanismsGene therapy reprograms stem cells to produce healthy red blood cells.
Target PopulationPrimarily Black Americans with sickle cell disease, approximately 100,000 individuals.
Care SettingSpecialized hospitals offering gene therapy.

Key Highlights

  • Gene therapies approved for patients 12 years and older.
  • Cost of therapies ranges from $2.2 million to $3.1 million per patient.
  • New payment model holds drug manufacturers accountable for treatment success.
  • Medicaid covers about half of Americans with sickle cell disease.
  • Potential to avoid hospitalizations and improve quality of life.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of sickle cell disease through blood tests.

Management

  • Gene therapy as a potential cure for eligible patients.

Monitoring & Follow-up

  • Federal evaluation to track patient outcomes and treatment effectiveness.

Risks

  • Limited number of hospitals offering therapy and potential complications from treatment.

Patient & Prescribing Data

Medicaid enrollees with sickle cell disease.

Gene therapy offers a chance to live without pain and complications.

Clinical Best Practices

  • Monitor patient outcomes to ensure treatment efficacy.
  • Consider fertility preservation options for patients undergoing chemotherapy.

References

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.